Stay updated on DS-1062a in Advanced Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the DS-1062a in Advanced Solid Tumors Clinical Trial page.

Latest updates to the DS-1062a in Advanced Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content with a minimal error screen. The new screen includes a Home link and reflects restricted access to the page.SummaryDifference21%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedNew date entries were added to the study record to reflect recent updates and milestone estimates, while older date entries were removed. This indicates refreshed metadata about when updates were posted and when key study milestones (e.g., primary completion and study completion) are expected.SummaryDifference0.3%

- Check35 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6, indicating a software or content update behind the page. This is metadata about the page version and does not alter the displayed study information.SummaryDifference0.0%

- Check57 days agoChange DetectedThe site revision label was updated from v3.6.4 to v3.6.5. This indicates a new release of the page/component.SummaryDifference0.0%

- Check71 days agoChange DetectedThe page’s revision indicator updated from v3.6.3 to v3.6.4, signaling a new build of the page. This appears to be a behind-the-scenes update rather than a change to the study data presented on the page.SummaryDifference0.0%

- Check93 days agoChange DetectedA new site revision tag, v3.6.3, was added to the page, replacing the previous v3.6.2. This indicates a minor update to the ClinicalTrials.gov interface without altering study details.SummaryDifference0.0%

Stay in the know with updates to DS-1062a in Advanced Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DS-1062a in Advanced Solid Tumors Clinical Trial page.